ClinicalTrials.gg
Enrolling by invitationNCT06649799Updated Oct 21, 2024

Comparative Study on Changes in Anterior Chamber Cytokines, Oxidative Stress, and Pupil Size After LenSx and Z8 Femtosecond Lasers

An interventional study of LenSx and Z8 in Cataract, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Enrolling by invitation at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University — 6 open to participants now, 6 under way, none of them phase 3. Cataract · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Started
2024
with 3 others
No phase
8 of 11
4 open now
Registered
8th of 11
by date

Among the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is one of 4 that started in 2024, is one of 8 with no phase, and was the 8th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

6 of the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

Femtosecond laser-assisted cataract surgery is rapidly gaining popularity. Among the 5 femtosecond laser platforms available at present for cataract surgery, the Femto LDV Z8 (Ziemer Ophthalmic Systems AG) is a high-frequency system and delivers energy pulses in nanojoule levels, while Lensx platform (Lensx, Alcon Laboratories, Inc.) used a high-energy laser system. In femtosecond laser-assisted cataract surgery, the laser pretreatment is associated with breakdown of blood-aqueous barrier (BAB) associated with increased aqueous total prostaglandin, cytokines and Oxygen-free radicals concentration. The prostaglandin rise immediately after laser pretreatment is further thought to be the causative factor for the intraoperative miosis in femtosecond laser-assisted cataract surgery. However, the analysis of anterior chamber inflammatory factors, oxidative stress, and pupil size after femtosecond laser-assisted cataract surgery between different laser platforms has not been investigated in clinical studies. Understanding the cytokine and chemokine changes related to the laser pretreatment provides better insight into the inflammatory response in femtosecond laser-assisted cataract surgery.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • cataract; femtosecond laser; cytokines; oxidative stress; miosis;
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age related cataracts over 50 years old, nuclear grades II-III

Exclusion criteria

Exclusion Criteria:

  • Eye diseases: glaucoma, uveitis

    • Systemic diseases: diseases such as diabetes and rheumatism ③ Intraoperative complications: ④ Medication history: Over 1 month before surgery, systemic or local hormones, NASIDs ⑤ History of eye surgery (including YAG laser and fundus laser), trauma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    LenSx

    Device: LenSx

  • Placebo comparator
    Z8

    Device: Z8

Interventions

  • DeviceLenSx

    The patients in Group 1 conduct FLACS under LenSx

  • DeviceZ8

    The patients in Group 1 conducted FLACS using Z8

06

What researchers measure

Primary outcomes

  1. PGE2

    The concentrations of PGE2 in aqueous humor

    Time frame: through study completion, an average of half a year

  2. cytokines (IL-1β、IL-6, IL-8、TNF-a)

    The concentrations of cytokines (IL-1β、IL-6, IL-8、TNF-a) in aqueous humor

    Time frame: through study completion, an average of half a year

  3. MDA

    The concentrations of MDA in aqueous humor

    Time frame: through study completion, an average of half a year

Secondary outcomes

  1. central corneal thickness

    The central corneal thickness was measured

    Time frame: through study completion, an average of half a year

  2. central macular thickness

    The central macular thickness was measured

    Time frame: through study completion, an average of half a year

07

Study locations

1 site
  • ye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2025, 10 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 10 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 21, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649799
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Aug 1, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 21, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion